Reply to Nemeth et al. “The ERIKA trial: still limited evidence on the efficacy of thromboprophylaxis after knee arthroscopy”

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Thromb Haemost 2016; 116(05): 1002
DOI: 10.1160/TH16-08-0649

Author Correspondence

Schattauer GmbH

Giuseppe Camporese

¹Unit of Angiology, Department of Cardiac, Thoracic and Vascular Sciences, University Hospital of Padua, Padua, Italy

,

Enrico Bernardi

²Emergency and Accident Medicine, Hospital of Conegliano, Conegliano, Italy

,

Franco Noventa

³Department of Molecular Medicine, University-Hospital of Padova, Padova, Italy

Further Information

Received: 19 August 2016

Accepted after major revision: 01 September 2016

Publication Date:
30 November 2017 (online)

References
1 Nemeth B, van Adrichem R, Cannegieter SC. The ERIKA trial: still limited evidence on the efficacy of thromboprophylaxis after knee arthroscopy. Thromb Haemost 2016; 116: 1001.

Article in Thieme Connect PubMed Google Scholar
2 Camporese G, Bernardi E, Noventa F. et al. Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA Study). Thromb Haemost 2016; 116: 349-355.

Article in Thieme Connect PubMed Google Scholar